ENTPD1 and neoplasm: In a variety of malignancies, tumor-derived EVs, can be coated with the ecto-nucleotidases CD39 and CD73, which can suppress anti-tumor effector responses as well as promote the enhanced activity of regulatory T cells through extracellular ATP manipulation (68–70).